Article

Transplacental Pharmacokinetics of Glyburide, Rhodamine 123, and BODIPY FL Prazosin: Effect of Drug Efflux Transporters and Lipid Solubility

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic.
Journal of Pharmacology and Experimental Therapeutics (Impact Factor: 3.86). 09/2009; 331(3):1118-25. DOI: 10.1124/jpet.109.160564
Source: PubMed

ABSTRACT Breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) are the most abundantly expressed ATP-binding cassette (ABC) drug transporters in the placenta. They recognize a large, partly overlapping spectrum of chemically unrelated compounds and affect their transplacental passage. In this study we investigate the effect of Bcrp and P-gp on the transplacental pharmacokinetics of their specific and common substrates employing the technique of dually perfused rat placenta. We show that the clearance of rhodamine 123 (P-gp substrate), glyburide (BCRP substrate) and BODIPY FL prazosin (P-gp and BCRP substrate) in fetal-to-maternal direction is 11, 11.2 and 4 times higher, respectively, than that in the maternal-to-fetal direction. In addition, all of these substances were found to be transported from the fetal compartment even against concentration gradient. We thus demonstrate the ability of placental ABC transporters to hinder maternal-to-fetal and accelerate fetal-to-maternal transport in a concentration-dependent manner. However, by means of pharmacokinetic modeling we describe the inverse correlation between lipid solubility of a molecule and its active transport by placental ABC efflux transporters. Therefore, in the case of highly lipophilic substrates, such as BODIPY FL prazosin in this study, the efficacy of efflux transporters to pump the molecule back to the maternal circulation is markedly limited.

0 Followers
 · 
183 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug permeability in the central nervous system (CNS) across blood-brain and blood-cerebrospinal fluid barriers is an important determinant of neurological disorders therapeutic efficacy and is highly regulated by the expression of membrane-associated transporters belonging to the ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies. Functional expression of ABC efflux transporters exists not only at the brain barriers (primary biochemical barrier) but also in astrocytes, microglia, neurons, and oligodendrocytes can significantly restrict drug penetration into these cells, thus creating a secondary biochemical barrier to permeability in brain parenchyma. In contrast, SLC members primarily contribute to the uptake of endogenous substrates (i.e., hormones, neurotransmitters) and pharmacological agents and can play a critical role in maintaining CNS homeostasis and drug response. In this chapter, we review the functional expression and localization of drug transporters in the brain, their role in CNS drug delivery, and their regulation in neuropathological conditions.
    Advances in pharmacology (San Diego, Calif.) 01/2014; 71C:45-111. DOI:10.1016/bs.apha.2014.06.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: La prise de médicaments chez la femme enceinte soulève la question des risques potentiels pour le fœtus et, en préalable, celle d’un éventuel passage placentaire du traitement. Outre son rôle dans le transfert de nutriments et l’élimination de produits de dégradation foetale, une fonction de barrière protectrice lui est également attribuée. Or, cette notion de « barrière » est impropre au regard des nombreux échanges possibles entre la mère et le foetus, y compris médicamenteux. Abstract Treatment in pregnant women raises the question of induced fetal risks due to a possible placental transfer of drugs. In addition to its role in nutrients’ supply and removal of degradation products, a protective barrier function has been attributed to the placenta. But the term “barrier” seems inappropriate given the large exchanges between the mother and her fetus.
    Revue de médecine périnatale 03/2014; 6(1):12-20. DOI:10.1007/s12611-014-0271-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The xenobiotic transporters are among the most important constituents of detoxification system in living organisms. Breast cancer resistance protein (BCRP/ABCG2) is one of the major transporters involved in the efflux of xenobiotics. To understand its role in chemotherapeutic and multidrug resistance, it is crucial to establish the determinants of its substrate specificity, which obviously is of high relevance for successful therapy of many diseases. This article summarizes the current knowledge about the substrate preferences of BCRP. We overview the factors which determine its activity, inhibition and substrate recognition, focusing on the structural features of the transporter. BCRP substrate specificity is quite low as it interacts with a spectrum of substances with only a few common features: hydrophobic and aromatic regions, possibly a flat conformation and the metal ion-, oxygen- and nitrogen-containing functionalities, most of which may be the donors/acceptors of H-bonds. Several amino acid residues and structural motifs are responsible for BCRP activity and substrate recognition. Thus, the active form of BCRP, at least a dimer or a larger oligomer is maintained by intramolecular disulfide bridge that involves Cys(603) residues. The GXXXG motif in transmembrane helix 1, Cys residues, Arg(482) and Lys(86) are responsible for maintaining the protein structure, which confers transport activity, and the His(457) or Arg(456) residues are directly involved in substrate binding. Arg(482) does not directly bind substrates, but electrostatically interacts with charged molecules, which initiates the conformational changes that transmit the signal from the transmembrane regions to the ABC domain.
    Drug Metabolism Reviews 07/2014; 46(4):1-16. DOI:10.3109/03602532.2014.942037 · 6.29 Impact Factor

Full-text

Download
77 Downloads
Available from
May 23, 2014